The Latest Human Milk Oligosaccharides Industry Statistics Explained
The global human milk oligosaccharides (HMO) market size was valued at USD 65.5 million in 2020.
The statistic indicates that the global market for human milk oligosaccharides (HMO) reached a value of USD 65.5 million in 2020. HMOs are complex sugars found in breast milk that play a crucial role in supporting the growth of beneficial gut bacteria in infants, promoting healthy development and immunity. The market size represents the total revenue generated from the sale of HMO products and is a reflection of the growing recognition of the health benefits associated with HMO consumption. The increasing demand for HMOs, potentially driven by their perceived health advantages and advancements in technology for HMO production, has contributed to the market’s substantial value. The statistic serves as an important indicator of the market’s significance and potential for further growth in the coming years.
There is an expected Compound Annual Growth Rate (CAGR) of 22% for the HMO industry from 2021 to 2028.
The statement indicates that analysts project the HMO industry to experience a Compound Annual Growth Rate (CAGR) of 22% on average between the years 2021 and 2028. This suggests that the industry is anticipated to expand rapidly during this period, with year-over-year growth reaching an annualized rate of 22%. Such a high CAGR implies substantial growth potential and market opportunity within the HMO sector, likely driven by factors such as increasing healthcare needs, changing regulatory environments, technological advancements, or shifting consumer preferences. Investors, policymakers, and industry stakeholders can use this statistic to make informed decisions regarding investments, resource allocations, or strategic planning within the HMO industry.
The projected size of the HMO market by 2028 is USD 251.4 million.
The statistic ‘The projected size of the HMO market by 2028 is USD 251.4 million’ indicates the anticipated total value of the Health Maintenance Organization (HMO) market by the year 2028. This figure represents the estimated financial scale of HMOs providing healthcare services in that year, encompassing revenue generated from premiums, services, and other sources. The projection of USD 251.4 million suggests a substantial market size and signifies potential growth and opportunities within the HMO sector over the next few years, reflecting the demand for managed care services and the evolving landscape of the healthcare industry.
Europe held a leading market share of around 38% in 2020 in the HMO industry.
The statistic indicates that Europe had the highest market share among all regions in the Health Maintenance Organization (HMO) industry in 2020, accounting for approximately 38% of the total market. This implies that Europe was the dominant player in providing managed healthcare services through HMOs compared to other regions globally. The high market share suggests that HMOs in Europe were preferred by consumers and healthcare providers, potentially due to factors such as comprehensive coverage, quality services, or regulatory environment. This statistic highlights the strong presence and influence of the European HMO market within the broader healthcare industry landscape in 2020.
Infant formula is projected to be the fastest-growing segment in the HMO market with a CAGR of 22.5% from 2021 to 2028.
The statistic indicates that the infant formula segment within the Health Maintenance Organization (HMO) market is expected to experience significant growth over the period from 2021 to 2028. The Compound Annual Growth Rate (CAGR) of 22.5% implies that the market size for infant formula is projected to expand rapidly during this time frame. Factors such as increasing demand for infant nutrition products, changes in consumer preferences, and innovative product developments are likely driving this growth trend. This statistic suggests a favorable outlook for companies operating within the infant formula market, highlighting potential opportunities for expansion and investment in this segment of the HMO market.
The revenue generated from the sales of the HMO for infant formula is predicted to reach nearly USD 143 million by 2028.
The statistic indicates that the revenue generated from sales of infant formula by the Health Maintenance Organization (HMO) is projected to nearly reach USD 143 million by the year 2028. This prediction suggests a substantial growth in revenue for the HMO in the market segment of infant formula over the next few years. Factors such as increasing demand for infant formula, the HMO’s market share in this sector, and potential strategic developments could be contributing to this upward trend in revenue. Monitoring and analyzing such projections are essential for the HMO to make informed business decisions and ensure continued success in the infant formula market.
In 2020, Glycom A/S had the largest market share for HMO, leading by 35.2%.
This statistic indicates that in the year 2020, Glycom A/S held the largest portion of the market share for Human Milk Oligosaccharides (HMO), amounting to 35.2%. This means that out of all the companies competing in the HMO market, Glycom A/S had the highest share of customers or revenue. The significant lead of 35.2% suggests that Glycom A/S was particularly successful in capturing a substantial portion of the market relative to its competitors, positioning the company as a key player in the HMO industry in 2020.
By 2024, it is predicted that North America will surpass Europe and hold the largest market share for HMO.
The statistic predicts that by the year 2024, North America will overtake Europe to become the region with the largest market share for Health Maintenance Organizations (HMO). This suggests a trend or shift in the market dynamics, potentially driven by factors such as changes in healthcare regulations, consumer preferences, or the performance and growth of HMOs in North America. It implies that the North American healthcare market for HMO services is expected to expand and grow at a faster rate compared to Europe over the specified timeframe, highlighting opportunities and competition in the healthcare industry across these regions.
The 2’-Fucosyllactose (2’FL) segment dominated the HMO market with more than 49% market share and is expected to register the highest CAGR during the forecast period.
This statistic indicates that the 2’-Fucosyllactose (2’FL) segment is currently the leading category within the human milk oligosaccharides (HMO) market, holding a significant market share of over 49%. Moreover, it is projected to experience the highest Compound Annual Growth Rate (CAGR) compared to other HMO segments in the foreseeable future. This suggests that there is a strong demand for products containing 2’FL, likely due to its perceived health benefits and functional properties. Companies operating in the HMO market may strategize to capitalize on the growth potential of the 2’FL segment to maintain or enhance their market position.
The food & beverage industry has adopted HMO applications, and it’s poised to reach USD 96.8 million by 2028.
This statistic indicates that the food & beverage industry has increasingly incorporated Human Milk Oligosaccharides (HMO) applications into their products, with a projected market value set to reach USD 96.8 million by 2028. HMOs are complex carbohydrates naturally found in human breast milk that offer various health benefits, including promoting a healthy gut microbiome and supporting the immune system. The industry’s adoption of HMO applications suggests a growing recognition of the potential benefits these ingredients can offer in enhancing the nutritional value and health-promoting properties of food and beverage products. The projected market value demonstrates the significant investment and growth potential within the sector, indicating a shift towards more innovative and health-conscious offerings in the market.
By 2028, the HMO sales for dietary supplements are expected to reach nearly USD 58 million.
The statistic states that the sales of dietary supplements through Health Maintenance Organizations (HMOs) are projected to increase to almost USD 58 million by the year 2028. This figure indicates a predicted growth in consumer demand for dietary supplements distributed through HMO channels over the next several years. This trend could be driven by factors such as increasing awareness of the importance of health and wellness, a growing aging population seeking to maintain their health, and potentially shifting consumer preferences towards preventive healthcare strategies. The expected rise in HMO dietary supplement sales highlights a potential market opportunity for healthcare providers and supplement manufacturers to cater to the evolving needs and preferences of consumers seeking nutritional and wellness support through this distribution channel.
Among various industries, the pharmaceutical industry saw the highest adoption of HMOs in 2020, accounting for 41.2% of the market.
The statistic indicates that in 2020, the pharmaceutical industry had the highest proportion of Health Maintenance Organization (HMO) adoption compared to other industries, with 41.2% of the market share. This suggests that a significant portion of pharmaceutical companies and employees within the industry opted for HMO health insurance plans over other types of insurance options. The high adoption rate could be attributed to various factors such as the nature of work in the pharmaceutical industry, employee demographics, as well as the benefits and cost-effectiveness of HMO plans. This statistic highlights the importance of understanding industry-specific trends and preferences when analyzing health insurance adoption rates.
Asia-Pacific is expected to exhibit the highest growth rate of 24.9% in the HMO market during the forecast period.
This statistic indicates that the Asia-Pacific region is projected to experience the most significant increase in the Health Maintenance Organization (HMO) market over the forecast period, with a growth rate of 24.9%. This suggests a strong demand for HMO services in the Asia-Pacific region, potentially driven by factors such as increasing awareness of the benefits of preventive healthcare, rising healthcare expenditures, and evolving healthcare infrastructure in this region. The high growth rate indicates that HMOs are likely to be increasingly popular and adopted by individuals and healthcare providers in the Asia-Pacific region, leading to substantial market expansion and potentially improved access to comprehensive and cost-effective healthcare services for populations in this area.
Japan dominated the Asia Pacific HMO market share of 39.8% in 2020.
The statistic “Japan dominated the Asia Pacific HMO market share of 39.8% in 2020” indicates that Japan held a significant portion of the market share for Health Maintenance Organizations (HMOs) in the Asia Pacific region during the year 2020. This suggests that Japan had a strong presence and influence in providing healthcare services through the HMO model compared to other countries in the region. With nearly 40% market share, Japan was a key player in shaping the healthcare landscape and driving the trends and developments within the Asia Pacific HMO market in 2020.
The commercial production of HMO started around 2015.
The statement “The commercial production of HMO started around 2015” implies that the manufacturing of Human Milk Oligosaccharides (HMO), a type of complex carbohydrate found in breast milk with potential health benefits, began to be done on a large scale for commercial purposes around the year 2015. This statistic indicates that before 2015, HMO may have been predominantly produced on a smaller scale or for research purposes, but starting around 2015, there was a notable increase in the industrial production of HMO for commercial distribution and use in various products such as infant formula and dietary supplements.
Revenue from pharmaceutical applications of HMO is expected to amount to USD 104.4 million by 2028.
The statistic indicates that the revenue generated from pharmaceutical applications of health maintenance organizations (HMO) is projected to reach USD 104.4 million by the year 2028. This suggests an anticipated growth in the income generated by HMO services related to pharmaceuticals. The increase in revenue could be attributed to factors such as the rising demand for pharmaceutical products within HMO networks, advancements in healthcare technology, and potentially an expansion of the customer base for such services. This statistic underscores the potential economic impact of HMOs in the pharmaceutical sector and highlights the importance of these organizations in delivering healthcare services to the public.
Demand for lacto-N-neotetraose (LNnT) HMO category is predicted to reach $12.6 million by 2026 on a global scale.
The statistic that demand for lacto-N-neotetraose (LNnT) HMO category is predicted to reach $12.6 million by 2026 on a global scale indicates the anticipated market value for this specific category of human milk oligosaccharides. This prediction suggests that there is growing interest and demand for LNnT, likely driven by factors such as increased awareness of its potential health benefits and applications. The projected value of $12.6 million by 2026 suggests a significant market opportunity for products containing LNnT, prompting potential investment and development in this area to meet the expected demand.
In 2020, the sales of HMOs in Latin America reached USD 3.4 million.
The statistic ‘In 2020, the sales of HMOs in Latin America reached USD 3.4 million’ indicates that the total revenue generated by HMOs (Health Maintenance Organizations) in Latin America during the year 2020 was approximately USD 3.4 million. This figure represents the combined sales of all HMOs operating in the region over the course of the year. It provides insight into the financial performance and market size of the HMO industry in Latin America, highlighting the significant economic activity and consumer demand for healthcare services provided by HMOs in the region during the specified time period.
China is predicted to grow nearly 1.5 times the global market rate by 2026 in the HMO industry.
The statistic indicates that by 2026, the Health Maintenance Organization (HMO) industry in China is forecasted to expand at a rate that is nearly 1.5 times faster than the global market growth rate. This suggests that the HMO industry in China is expected to experience significant growth and outperform the global average rate of growth in the same industry by a considerable margin. Factors contributing to this anticipated growth could include increasing demand for healthcare services, potential policy changes, advancements in technology, and a growing focus on preventative healthcare measures within the Chinese market. This prediction highlights the potential opportunities for investment and expansion within the HMO industry in China in the coming years.
References
0. – https://www.www.grandviewresearch.com
1. – https://www.www.visionresearchreports.com
2. – https://www.www.mordorintelligence.com
3. – https://www.www.adroitmarketresearch.com
4. – https://www.www.meticulousresearch.com
5. – https://www.www.marketresearchengine.com
6. – https://www.www.arcognizance.com
7. – https://www.www.ncbi.nlm.nih.gov
8. – https://www.www.fortunebusinessinsights.com
9. – https://www.www.advancemarketanalytics.com
10. – https://www.www.marketstudyreport.com
11. – https://www.www.factmr.com
12. – https://www.www.marketdataforecast.com
